ΔCS-PP
An experimental COVID-19 protein vaccine.
General information
ΔCS-PP is an experimental anti-SARS-CoV-2 vaccine based on modified Spike protein adjuvanted with AddaVax (oil in water emulsion formulation). The Spike modifications include the replacement of the polybasic cleavage site with a single alanine (ΔCS) and exchange of K986 and V987 with two prolines (PP). The experimental vaccine displayed higher efficacy compared to the adjuvanted wild type Spike or ΔCS- or PP-alone Spike in a mouse model (Amanat et al., 2021).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model
Spike protein Protein factor Animal model In vitro |
in vitro binding assay; Vero E6 cells; hACE2-expressing (transiently) BALB/c mice; SARS-CoV-2 isolate USA‐WA1/2020 | 6.78 | The experimental vaccine displayed higher efficacy in a mouse model compared to the adjuvanted wild type Spike or ΔCS- or PP-alone Spike. The sera of the vaccinated mice displayed high RBD-binding and neutralizing activity. The vaccinated mice experienced minimal weight loss, showed few signs of lung pathology and their SARS-CoV-2 titres were below detection limit 2 days post viral challenge. |
Mar/02/2021 |
